Bilirubin treatment decreases fasting glucose, body weight, body fat and increases fatty acid oxidation in mice: effects that are mirrored by canagliflozin treatment [16,62,64] Collectively, these actions of HO-1 and its products may contribute to the beneficial cardiometabolic outcomes in patients with T2DM that are administered canagliflozin. The gene discussed is HMOX1; the disease is type 2 diabetes mellitus.